Compass Pathways (
NASDAQ:CMPS) and Greenbrook TMS (
NASDAQ:GBNH) on Friday announced that they have entered into a three-year research collaboration agreement to explore delivery models for investigational COMP360 psilocybin treatment (“COMP360”) upon regulatory approval by the U.S. Food and Drug Administration. The collaboration will research and investigate models for the delivery of scalable, commercial COMP360 within healthcare systems, assuming FDA approval. GBNH
+2.34% premarket to $0.2751. Source: Press Release
More on COMPASS Pathways ADS, Greenbrook, etc.